BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 17295433)

  • 1. Serum sickness following treatment with rituximab.
    Todd DJ; Helfgott SM
    J Rheumatol; 2007 Feb; 34(2):430-3. PubMed ID: 17295433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab-induced severe acute thrombocytopenia: a case report and review of literature.
    Dhand S; Bahrain H
    Cancer Invest; 2008 Nov; 26(9):913-5. PubMed ID: 19034773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies].
    Matsui T; Hidaka M; Kawakita T; Inoue Y; Sakai T; Harada N; Takemoto S; Nagakura S; Tsukamoto A; Kiyokawa T; Kawano F
    Rinsho Ketsueki; 2009 Apr; 50(4):304-8. PubMed ID: 19404025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
    Le Guenno G; Ruivard M; Charra L; Philippe P
    Intern Med J; 2011 Feb; 41(2):202-5. PubMed ID: 22747556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab-induced serum sickness.
    Schutgens RE
    Br J Haematol; 2006 Oct; 135(2):147. PubMed ID: 16869826
    [No Abstract]   [Full Text] [Related]  

  • 7. Remarkable response to rituximab in a patient with atypical CD20(++) mantle cell lymphoma of the bone marrow leading to severe pancytopenia.
    Seggewiss R; Ho AD; Kraemer A
    Ann Hematol; 2004 May; 83(5):316-8. PubMed ID: 15064861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma.
    Arai Y; Tadokoro J; Mitani K
    Am J Hematol; 2005 Apr; 78(4):317-8. PubMed ID: 15795913
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab-induced serum sickness.
    Herishanu Y
    Am J Hematol; 2002 Aug; 70(4):329. PubMed ID: 12214584
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum sickness due to infliximab in a patient with psoriasis.
    Krishnan RS; Hsu S
    J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.
    Finger E; Scheinberg M
    J Clin Rheumatol; 2007 Apr; 13(2):94-5. PubMed ID: 17414540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab).
    D'Arcy CA; Mannik M
    Arthritis Rheum; 2001 Jul; 44(7):1717-8. PubMed ID: 11465726
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response.
    Crysandt M; Neumann B; Das M; Engelbertz V; Bendel M; Galm O; Osieka R; Jost E
    Eur J Haematol; 2007 Dec; 79(6):546-9. PubMed ID: 17903214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
    Biehn SE; Kirk D; Rivera MP; Martinez AE; Khandani AH; Orlowski RZ
    Hematol Oncol; 2006 Dec; 24(4):234-7. PubMed ID: 16948177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.
    Quartier P; Tournilhac O; Archimbaud C; Lazaro L; Chaleteix C; Millet P; Peigue-Lafeuille H; Blanche S; Fischer A; Casanova JL; Travade P; Tardieu M
    Clin Infect Dis; 2003 Feb; 36(3):e47-9. PubMed ID: 12539090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in immunotherapy rituximab.
    El-Habbash MM; Alwindi AM
    Saudi Med J; 2007 Nov; 28(11):1635-44. PubMed ID: 17965780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
    Ram R; Bonstein L; Gafter-Gvili A; Ben-Bassat I; Shpilberg O; Raanani P
    Am J Hematol; 2009 Apr; 84(4):247-50. PubMed ID: 19260124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
    Christopeit M; Haak U; Behre G
    Ann Hematol; 2008 Sep; 87(9):761-2. PubMed ID: 18350295
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab-induced serum sickness in a patient with follicular lymphoma.
    Disperati P; Hicks LK; Buckstein R
    Leuk Lymphoma; 2007 Aug; 48(8):1633-5. PubMed ID: 17701597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.